Posted by Michael Wonder on 14 Dec 2023
Glaukos announces FDA approval of iDose TR (travoprost intracameral implant)
14 December 2023 - FDA approval based on robust Phase 3 clinical program consisting of two pivotal studies that randomised 1,150 subjects across 89 clinical sites.
Glaukos announced today the US FDA approved its new drug application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for the reduction of intra-ocular pressure in patients with ocular hypertension or open-angle glaucoma.
